Research
Dr. Gasoyan’s research focuses on access to care, comparative effectiveness and health outcomes with clinical applications to obesity, type 2 diabetes, multiple myeloma and related chronic diseases. The goal of his research is to help develop evidence-based recommendations for patient-centered care, improve population health outcomes and control healthcare costs.
Biography
Dr. Hamlet Gasoyan is a health services researcher at the Center for Value-Based Care Research in the Department of Internal Medicine of Cleveland Clinic’s Primary Care Institute and assistant professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. His research focuses on access to care, comparative effectiveness, and health outcomes with clinical applications to obesity, type 2 diabetes, blood cancer, and related chronic diseases. The goal of his research is to help develop evidence-based recommendations for patient-centered care, improve population health outcomes, and control healthcare costs. Dr. Gasoyan’s articles have been published in leading medical and health policy peer-reviewed journals such as JAMA, Nature Medicine, and Health Affairs and received coverage by national and local news organizations. His research has been funded by the National Institutes of Health, as well as other competitive grants.
Education & Professional Highlights
Postdoctoral Training – Washington University School of Medicine in St. Louis
Health Services Research
St. Louis, MO USA
2021–2022
Graduate School – Temple University, College of Public Health
Health Policy and Health Services Research
Philadelphia, PA USA 2021
Graduate School – University of South Florida, College of Public Health
Health Care Organizations and Management
Tampa, FL USA 2014
Residency – Yerevan State Medical University
Prosthodontics
Yerevan, Armenia
2009–2012
Graduate School – Yerevan State Medical University
Stomatology
Yerevan, Armenia
2009
Research
Research
Developing evidence-based recommendations on next steps after novel obesity medication discontinuation
Novel obesity medications have demonstrated 15–21% weight reductions and are in high demand, but two-thirds of patients stop taking them within a year. There is a lack of evidence about what patients should do next. This project examines the natural history and comparative effectiveness of treatment alternatives after novel obesity medication discontinuation and patient priorities when choosing an alternative treatment for obesity.
Funding: Cleveland Clinic – Jack, Joseph and Morton Mandel Accelerator Grants
Real-world treatment outcomes for multiple myeloma in the era of novel therapies
Overall survival with multiple myeloma has improved considerably over the past two decades, thanks to advances in treatment. This project examines the utilization patterns of therapies for multiple myeloma, modifiable barriers to timely care, and comparative effectiveness of available treatment strategies.
Funding: National Cancer Institute
Selected Publications
View publications for Hamlet Gasoyan, PhD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)